CSIMarket
Bristol Myers Squibb Co  (BMY)
Other Ticker:  
 
 

Bristol Myers Squibb Co's Suppliers Performance

BMY's Supply Chain

 
BMY Costs vs Sales of Suppliers Growth Bristol Myers Squibb Co's Suppliers recorded increase in sales by 26.89 % year on year in Q3 2021, sequentially sales grew by 2.48 %, Bristol Myers Squibb Co's cost of sales deteriorated by % year on year, compare to one quarter ago cost of sales fell by -6.57 % in Q3.

More on BMY Suppliers




Bristol Myers Squibb Co's Suppliers recorded increase in sales by 26.89 % year on year in Q3 2021, sequentially sales grew by 2.48 %, Bristol Myers Squibb Co's cost of sales deteriorated by -8.43 % year on year, compare to one quarter ago cost of sales fell by -6.57 % in Q3.

More on BMY Suppliers




Bristol Myers Squibb Co's Comment on Supply Chain


In general, we purchase our raw materials and supplies required for the production of our products in the open market. For some products, we purchase our raw materials and supplies from one source (the only source available to us) or a single source (the only approved source among many available to us), thereby requiring us to obtain such raw materials and supplies from that particular source. We attempt, if possible, to mitigate our raw material supply risks, through inventory management and alternative sourcing strategies.

To meet all expected product demand, we operate and manage our manufacturing network, including our third-party contract manufacturers, and the inventory related thereto, in a manner that permits us to improve efficiency while maintaining flexibility to reallocate manufacturing capacity. Pharmaceutical production processes are complex, highly regulated and vary widely from product to product. Given that shifting or adding manufacturing capacity can be a lengthy process requiring significant capital and other expenditures as well as regulatory approvals, we maintain and operate our flexible manufacturing network, consisting of internal and external resources that minimize unnecessary product transfers and inefficient uses of manufacturing capacity. For further discussion of the regulatory impact on our manufacturing, see “—Government Regulation and Price Constraints” above.

Our pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, France, Italy, Ireland, Japan, Mexico and China and require significant ongoing capital investment for both maintenance and compliance with increasing regulatory requirements. In addition, as our product line changes over the next several years, we expect to continue modification of our existing manufacturing network to meet complex processing standards that may be required for newly introduced products, including biologics. Biologics manufacturing involves more complex processes than those of traditional pharmaceutical operations. The FDA approved our large scale multi-product bulk biologics manufacturing facility in Devens, Massachusetts in May 2012 and we continue to make capital investments in this facility.

We rely on third parties to manufacture or supply us with all or a portion of the active ingredients necessary for us to manufacture various products, including Baraclude, the Sustiva Franchise, Erbitux*, Yervoy, Reyataz, Abilify*, Kombiglyze, Orencia, Eliquis, Avalide* and Plavix*. Beginning February 1, 2014, following the sale of our diabetes business to AstraZeneca, AstraZeneca assumed manufacturing responsibilities for Bydureon* and Byetta*.To maintain a stable supply of these products, we take a variety of actions including inventory management and maintenance of additional quantities of materials, when possible, designed to provide for a reasonable level of these ingredients to be held by the third-party supplier, us or both, so that our manufacturing operations are not interrupted. As an additional protection, in some cases, we take steps to maintain an approved back-up source where available. For example, we will rely on the capacity of our Devens, Massachusetts facility and the capacity available at our third-party contract manufacturers to manufacture Orencia.

If we or any third-party manufacturer that we rely on for existing or future products is unable to maintain a stable supply of products, operate at sufficient capacity to meet our order requirements, comply with government regulations for manufacturing pharmaceuticals or meet the complex processing requirements for biologics, our business performance and prospects could be negatively impacted. Additionally, if we or any of our third-party suppliers were to experience extended plant shutdowns or substantial unplanned increases in demand or suspension of manufacturing for regulatory reasons, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.

In connection with divestitures, licensing arrangements or distribution agreements of certain of our products, or in certain other circumstances, we have entered into agreements under which we have agreed to supply such products to third parties. In addition to liabilities that could arise from our failure to supply such products under the agreements, these arrangements could require us to invest in facilities for the production of non-strategic products, result in additional regulatory filings and obligations or cause an interruption in the manufacturing of our own products.

Our success depends in great measure upon customer confidence in the quality of our products and in the integrity of the data that support their safety and effectiveness. Product quality arises from a total commitment to quality in all parts of our operations, including research and development, purchasing, facilities planning, manufacturing, and distribution. We maintain quality-assurance procedures relating to the quality and integrity of technical information and production processes.

Control of production processes involves detailed specifications for ingredients, equipment and facilities, manufacturing methods, processes, packaging materials and labeling. We perform tests at various stages of production processes and on the final product to ensure that the product meets regulatory requirements and our standards. These tests may involve chemical and physical chemical analyses, microbiological testing, or a combination of these along with other analyses. Quality control is provided by business unit/site quality assurance groups that monitor existing manufacturing procedures and systems used by us, our subsidiaries and third-party suppliers.


Bristol Myers Squibb Co's Comment on Supply Chain


In general, we purchase our raw materials and supplies required for the production of our products in the open market. For some products, we purchase our raw materials and supplies from one source (the only source available to us) or a single source (the only approved source among many available to us), thereby requiring us to obtain such raw materials and supplies from that particular source. We attempt, if possible, to mitigate our raw material supply risks, through inventory management and alternative sourcing strategies.

To meet all expected product demand, we operate and manage our manufacturing network, including our third-party contract manufacturers, and the inventory related thereto, in a manner that permits us to improve efficiency while maintaining flexibility to reallocate manufacturing capacity. Pharmaceutical production processes are complex, highly regulated and vary widely from product to product. Given that shifting or adding manufacturing capacity can be a lengthy process requiring significant capital and other expenditures as well as regulatory approvals, we maintain and operate our flexible manufacturing network, consisting of internal and external resources that minimize unnecessary product transfers and inefficient uses of manufacturing capacity. For further discussion of the regulatory impact on our manufacturing, see “—Government Regulation and Price Constraints” above.

Our pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, France, Italy, Ireland, Japan, Mexico and China and require significant ongoing capital investment for both maintenance and compliance with increasing regulatory requirements. In addition, as our product line changes over the next several years, we expect to continue modification of our existing manufacturing network to meet complex processing standards that may be required for newly introduced products, including biologics. Biologics manufacturing involves more complex processes than those of traditional pharmaceutical operations. The FDA approved our large scale multi-product bulk biologics manufacturing facility in Devens, Massachusetts in May 2012 and we continue to make capital investments in this facility.

We rely on third parties to manufacture or supply us with all or a portion of the active ingredients necessary for us to manufacture various products, including Baraclude, the Sustiva Franchise, Erbitux*, Yervoy, Reyataz, Abilify*, Kombiglyze, Orencia, Eliquis, Avalide* and Plavix*. Beginning February 1, 2014, following the sale of our diabetes business to AstraZeneca, AstraZeneca assumed manufacturing responsibilities for Bydureon* and Byetta*.To maintain a stable supply of these products, we take a variety of actions including inventory management and maintenance of additional quantities of materials, when possible, designed to provide for a reasonable level of these ingredients to be held by the third-party supplier, us or both, so that our manufacturing operations are not interrupted. As an additional protection, in some cases, we take steps to maintain an approved back-up source where available. For example, we will rely on the capacity of our Devens, Massachusetts facility and the capacity available at our third-party contract manufacturers to manufacture Orencia.

If we or any third-party manufacturer that we rely on for existing or future products is unable to maintain a stable supply of products, operate at sufficient capacity to meet our order requirements, comply with government regulations for manufacturing pharmaceuticals or meet the complex processing requirements for biologics, our business performance and prospects could be negatively impacted. Additionally, if we or any of our third-party suppliers were to experience extended plant shutdowns or substantial unplanned increases in demand or suspension of manufacturing for regulatory reasons, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.

In connection with divestitures, licensing arrangements or distribution agreements of certain of our products, or in certain other circumstances, we have entered into agreements under which we have agreed to supply such products to third parties. In addition to liabilities that could arise from our failure to supply such products under the agreements, these arrangements could require us to invest in facilities for the production of non-strategic products, result in additional regulatory filings and obligations or cause an interruption in the manufacturing of our own products.

Our success depends in great measure upon customer confidence in the quality of our products and in the integrity of the data that support their safety and effectiveness. Product quality arises from a total commitment to quality in all parts of our operations, including research and development, purchasing, facilities planning, manufacturing, and distribution. We maintain quality-assurance procedures relating to the quality and integrity of technical information and production processes.

Control of production processes involves detailed specifications for ingredients, equipment and facilities, manufacturing methods, processes, packaging materials and labeling. We perform tests at various stages of production processes and on the final product to ensure that the product meets regulatory requirements and our standards. These tests may involve chemical and physical chemical analyses, microbiological testing, or a combination of these along with other analyses. Quality control is provided by business unit/site quality assurance groups that monitor existing manufacturing procedures and systems used by us, our subsidiaries and third-party suppliers.



BMY's Suppliers Net Income grew by BMY's Suppliers Net margin grew in Q3 to
51.94 % 13.65 %


Bristol Myers Squibb Co's Suppliers Sales Growth in Q3 2021 by Industry

Suppliers in Chemical Manufacturing Industry      28.52 %
Suppliers in Containers & Packaging Industry      22.31 %
Suppliers in Iron & Steel Industry      45.42 %
Suppliers in Miscellaneous Fabricated Products Industry      20.81 %
Suppliers in Miscellaneous Manufacturing Industry      22.88 %
Suppliers in Industrial Machinery and Components Industry      7.53 %
Suppliers in Food Processing Industry      51.7 %
Suppliers in Personal & Household Products Industry      36.1 %
Suppliers in Oil & Gas Integrated Operations Industry      56.32 %
Suppliers in Biotechnology & Pharmaceuticals Industry  
Suppliers in Environmental Services Industry      1.96 %
Suppliers in Communications Equipment Industry      20.46 %
Suppliers in Scientific & Technical Instruments Industry      9.49 %
Suppliers in Semiconductors Industry      21.44 %
Suppliers in Software & Programming Industry      24.29 %
     
• BMY Suppliers Valuation • BMY Segment Rev. Growth • BMY Segment Inc. Growth • BMY Suppliers Mgmt. Effect.





BMY's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Bristol Myers Squibb Co 140,556 45,468 -5,385 30,250
Bemis Co Inc 5,239 4,064 239 19,100
Corning Inc 34,365 13,756 1,671 50,110
Dow Inc 42,885 51,310 5,898 35,700
Eastman Chemical Co 16,471 9,968 521 14,500
Scully Royalty Ltd 103 46 0 0
Piedmont Lithium Inc 707 0 258 10,400
Sigma Aldrich Corp 0 4,724 491 9,300
Thermo Fisher Scientific Inc 227,020 39,059 8,565 75,000
Waters Corp 23,825 -1,135 594 7,500
Atyr Pharma Inc 110 10 -30 0
Illinois Tool Works Inc 74,699 14,251 2,727 44,000
Air Products And Chemicals Inc 62,319 10,323 2,115 19,275
Fmc Corporation 14,157 4,784 594 6,400
Airgas Inc 0 0 0 17,000
Danaher Corporation 197,660 28,065 5,885 60,000
Ashland Global Holdings Inc 102 2,111 220 11,000
Avery Dennison Corporation 16,678 8,216 749 30,000
Stericycle Inc 5,185 2,646 39 16,718
Om Group Inc 0 1,103 -80 6,200
Darling Ingredients Inc 10,630 4,451 546 10,000
United Guardian Inc 78 13 4 34
Cryoport inc 1,971 177 -33 31
Synalloy Corporation 150 295 4 411
Albemarle Corporation 24,096 3,313 292 6,000
Chemtura Corp 0 1,462 -893 2,500
Huntsman Corporation 7,843 7,814 857 15,000
Hawkins Inc 802 670 67 659
Quaker Chemical Corporation 3,710 1,681 131 2,020
Omnova Solutions Inc 455 723 -22 2,100
Stepan Company 2,640 2,231 152 2,073
Westlake Chemical Corporation 12,727 10,236 1,532 8,870
Westlake Chemical Partners Lp 936 1,068 364 141
Barnes Group Inc 2,336 1,237 89 5,036
Trecora Resources 200 256 0 310
Aspen Technology inc 9,659 730 326 1,419
Medidata Solutions Inc 5,752 685 44 1,680
Veeva Systems Inc 36,083 1,345 336 2,171
Photronics Inc 1,035 664 79 1,475
SUBTOTAL 842,628 232,352 34,329 494,133


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AREN's Profile

Stock Price

AREN's Financials

Business Description

Fundamentals

Charts & Quotes

AREN's News

Suppliers

AREN's Competitors

Customers & Markets

Economic Indicators

AREN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071